Hee-Jin Jang
YOU?
Author Swipe
View article: An Interpretable Multi-instance Learner Decodes Cellular Recruitment from Spatially Resolved Transcriptomics
An Interpretable Multi-instance Learner Decodes Cellular Recruitment from Spatially Resolved Transcriptomics Open
The recruitment of the various types of cells into the tissue microenvironment and how these cells engage with other cells in the tissue sites play critical biological roles. However, it is difficult to study these processes on a genome-wi…
View article: Gene expression in tumor and adjacent normal tissues in lung adenocarcinoma subtypes
Gene expression in tumor and adjacent normal tissues in lung adenocarcinoma subtypes Open
n We identified subtype-specific genes, biological functions, and potential drivers of subtype-specific carcinogenesis for LUAD subtypes. The study showed importance of gene expression in adjacent normal tissue for subtype-specific tumorig…
View article: Supplementary Data 2 from Ad-SGE-DKK3 Gene Therapy Overcomes Resistance to Immune Checkpoint Blockade in Pleural Mesothelioma
Supplementary Data 2 from Ad-SGE-DKK3 Gene Therapy Overcomes Resistance to Immune Checkpoint Blockade in Pleural Mesothelioma Open
Supplementary Data
View article: Supplementary Data 1 from Ad-SGE-DKK3 Gene Therapy Overcomes Resistance to Immune Checkpoint Blockade in Pleural Mesothelioma
Supplementary Data 1 from Ad-SGE-DKK3 Gene Therapy Overcomes Resistance to Immune Checkpoint Blockade in Pleural Mesothelioma Open
Supplementary methods, figures, and tables.
View article: Supplementary Data 3 from Ad-SGE-DKK3 Gene Therapy Overcomes Resistance to Immune Checkpoint Blockade in Pleural Mesothelioma
Supplementary Data 3 from Ad-SGE-DKK3 Gene Therapy Overcomes Resistance to Immune Checkpoint Blockade in Pleural Mesothelioma Open
Clinical Trial Protocol
View article: Data from Ad-SGE-DKK3 Gene Therapy Overcomes Resistance to Immune Checkpoint Blockade in Pleural Mesothelioma
Data from Ad-SGE-DKK3 Gene Therapy Overcomes Resistance to Immune Checkpoint Blockade in Pleural Mesothelioma Open
Purpose:Immune checkpoint inhibitors (ICI) have limited efficacy in pleural mesothelioma. We investigated the role of Dickkopf WNT signaling pathway inhibitor 3 (DKK3) in overcoming treatment resistance.Patients and Methods:We performed pr…
View article: Genome-wide association study for lung cancer in 6531 African Americans reveals new susceptibility loci
Genome-wide association study for lung cancer in 6531 African Americans reveals new susceptibility loci Open
Despite lung cancer affecting all races and ethnicities, disparities are observed in incidence and mortality rates among different ethnic groups in the United States. Non-Hispanic African Americans had a high incidence rate of lung cancer …
View article: Supplementary Methods S1 from A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma
Supplementary Methods S1 from A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma Open
Supplementary Methods
View article: Supplementary Figure S10 from A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma
Supplementary Figure S10 from A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma Open
Supplementary Figure 10. Presence of follicular helper T cells in CD57(+) T cells
View article: Supplementary Figure from Activation of Adaptive and Innate Immune Cells via Localized IL2 Cytokine Factories Eradicates Mesothelioma Tumors
Supplementary Figure from Activation of Adaptive and Innate Immune Cells via Localized IL2 Cytokine Factories Eradicates Mesothelioma Tumors Open
Supplementary Figure from Activation of Adaptive and Innate Immune Cells via Localized IL2 Cytokine Factories Eradicates Mesothelioma Tumors
View article: Supplementary Figure S2 from A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma
Supplementary Figure S2 from A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma Open
Supplementary Figure 2. Analysis scheme for imaging mass cytometry (IMC).
View article: Supplementary Figure S9 from A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma
Supplementary Figure S9 from A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma Open
Supplementary Figure 9. Alteration of naïve T (Tnaive) and stem cell-like memory T (Tscm) cells in PBMCs and BMMCs.
View article: Supplementary Table S7 from A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma
Supplementary Table S7 from A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma Open
Supplementary Table 7. CyTOF antibody panel for PBMC, BMMC, and tumor-infiltrating immune cells, relevant to Figure 4 and Figure 5.
View article: Supplementary Table S9 from A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma
Supplementary Table S9 from A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma Open
Supplementary Table 9. CyTOF antibody panel for PBMC, BMMC, and tumor-infiltrating immune cells, relevant to Supplementary Figure 10.
View article: Supplementary Table S4 from A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma
Supplementary Table S4 from A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma Open
Supplementary Table 4. Univariable analysis of variables associated with pathologic response and overall survival following neoadjuvant ICB (N=17).
View article: Supplementary Figure S3 from A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma
Supplementary Figure S3 from A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma Open
Supplementary Figure 3. Expression of pan-cytokeratin in sarcomatoid malignant pleural mesothelioma.
View article: Supplementary Figure from Activation of Adaptive and Innate Immune Cells via Localized IL2 Cytokine Factories Eradicates Mesothelioma Tumors
Supplementary Figure from Activation of Adaptive and Innate Immune Cells via Localized IL2 Cytokine Factories Eradicates Mesothelioma Tumors Open
Supplementary Figure from Activation of Adaptive and Innate Immune Cells via Localized IL2 Cytokine Factories Eradicates Mesothelioma Tumors
View article: Supplementary Table S3 from A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma
Supplementary Table S3 from A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma Open
Supplementary Table 3. Postoperative 30-day adverse events (AEs) observed after surgery.
View article: Supplementary Table S7 from A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma
Supplementary Table S7 from A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma Open
Supplementary Table 7. CyTOF antibody panel for PBMC, BMMC, and tumor-infiltrating immune cells, relevant to Figure 4 and Figure 5.
View article: Supplementary Table S6 from A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma
Supplementary Table S6 from A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma Open
Supplementary Table 6. CyTOF antibody panel for PBMC, relevant to Figure 4.
View article: Supplementary Table S4 from A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma
Supplementary Table S4 from A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma Open
Supplementary Table 4. Univariable analysis of variables associated with pathologic response and overall survival following neoadjuvant ICB (N=17).
View article: Supplementary Table S5 from A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma
Supplementary Table S5 from A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma Open
Supplementary Table 5. IMC antibody panel relevant to Figure 1 and Figure 3.
View article: Supplementary Figure S5 from A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma
Supplementary Figure S5 from A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma Open
Supplementary Figure 5. Overall survival of historical MPM cohorts
View article: Supplementary Figure S6 from A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma
Supplementary Figure S6 from A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma Open
Supplementary Figure 6. Germinal center containing Ki67(+) B cells and CD68(+) fDC-like cell meshwork in mature tertiary lymphoid structure.
View article: Supplementary Figure from Activation of Adaptive and Innate Immune Cells via Localized IL2 Cytokine Factories Eradicates Mesothelioma Tumors
Supplementary Figure from Activation of Adaptive and Innate Immune Cells via Localized IL2 Cytokine Factories Eradicates Mesothelioma Tumors Open
Supplementary Figure from Activation of Adaptive and Innate Immune Cells via Localized IL2 Cytokine Factories Eradicates Mesothelioma Tumors